Skip to content
Disclosery

EXANE DERIVATIVES: ECL position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on ECL, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 15 ECL shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 15 shares
    Change vs previous 13F -774 shares

    <0.01% of the 13F portfolio, value $2,306.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 789 shares
    Change vs previous 13F -115 shares

    0.04% of the 13F portfolio, value $139,307.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 904 shares
    Change vs previous 13F -256 shares

    0.05% of the 13F portfolio, value $212,076.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 1,160 shares
    Change vs previous 13F -1,718 shares

    0.06% of the 13F portfolio, value $242,007.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 2,878 shares
    Change vs previous 13F +1,563 shares

    0.14% of the 13F portfolio, value $612,306.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 1,315 shares
    Change vs previous 13F not available

    0.08% of the 13F portfolio, value $281,513.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).